CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 34 enrolled
Drug / intervention
Venlafaxine HCl +1 moredrug
Likely dose
Venlafaxine HCl 37.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00735670
NCT00735670N/ACompleted
CompareCT.gov

Treatment of Mild to Moderate Depression Symptoms in Patients With Spinal Cord Injury

University of Michigan·interventional·Posted Aug 15, 2008·Updated Oct 13, 2016

In Brief

A clinical study evaluating Venlafaxine HCl and Placebo for Spinal Cord Injury. Completed, enrolled 34 participants across 1 site.

Detailed Summary

This study was initially designed to test the efficacy of Venlafaxine HCl in reducing incidence of the onset of major depression after a new spinal cord injury (SCI). After several protocol modifications, the purpose of the study is to test the effectiveness of a sub-therapeutic dose of Venlafaxine HCl to reduce mild to moderate symptoms in persons with SCI.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSpinal Cord Injury
CountriesUnited States
CollaboratorsU.S. Department of Education

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 15, 2008
Enrollment StartJun 1, 2008
Primary CompletionJun 1, 2012
Study CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 17.9 years ago

Interventions

Venlafaxine HCldrug

Starting dose is 37.5 mg and ending dose is 150 mg at 13 weeks. From weeks 13 to 26 subjects no longer will receive the drug

Placeboother

Subjects received a placebo instead of Venlafaxine HCl until week 13 as did the Venlafaxine group.